Related Experiment Video
Updated: Jun 17, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib
Gianluca Tomasello1, Philippe L Bedard, Evandro de Azambuja
1Institut Jules Bordet, Université Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium. g.tomasello@ospedale.cremona.it
Abstract:
Due to improvements in diagnosis and systemic therapy, brain metastases are an increasingly common cause of morbidity and mortality for patients with advanced breast cancer. The incidence of symptomatic brain metastases among women with metastatic breast cancer ranges from 10% to 16%. The HER2 receptor, which is overexpressed in approximately 25% of all breast cancers, is an important risk factor for the development of central nervous system metastases. Surgery and radiation therapy are the primary approaches to the treatment of brain metastases but new chemotherapy and biological agents promise to play an important role in the future management of central nervous system disease. This article reviews the epidemiology, current treatment options and recent advances in the field, with a focus on HER2-positive disease and the emerging role of lapatinib for the treatment and prevention of brain metastases.
Insights
Brain metastases are a growing concern in advanced breast cancer, particularly HER2-positive cases. Emerging therapies like lapatinib show promise for treating and preventing brain metastases.
Area of Science:
- Oncology
- Neurology
- Breast Cancer Research
Background:
- Brain metastases are a significant cause of mortality in advanced breast cancer patients.
- The incidence of symptomatic brain metastases ranges from 10% to 16% in metastatic breast cancer.
- HER2 receptor overexpression (approx. 25% of breast cancers) is a key risk factor for CNS metastases.
Purpose of the Study:
- To review the epidemiology of brain metastases in breast cancer.
- To discuss current treatment options and recent advances for brain metastases.
- To focus on HER2-positive disease and the role of lapatinib.
Main Methods:
- Literature review of epidemiological data.
- Analysis of current treatment modalities (surgery, radiation, chemotherapy, biological agents).
- Focus on HER2-targeted therapies and lapatinib's role.
Main Results:
- Improvements in diagnosis and systemic therapy increase the incidence of brain metastases.
- HER2-positive status is strongly associated with central nervous system metastases.
- Lapatinib is an emerging agent for brain metastases treatment and prevention.
Conclusions:
- Brain metastases represent a critical challenge in advanced breast cancer management.
- HER2-targeted therapies, including lapatinib, offer new hope for HER2-positive patients.
- Future management will likely involve a combination of local therapies and novel systemic agents.
